Repligen Corp (RGEN) Com Stk USD0.01

Sell:$144.90Buy:$145.24$3.01 (2.13%)

NASDAQ:2.74%
Market closed | Prices delayed by at least 15 minutes
Sell:$144.90
Buy:$145.24
Change:$3.01 (2.13%)
Deal now
Market closed | Prices delayed by at least 15 minutes
Sell:$144.90
Buy:$145.24
Change:$3.01 (2.13%)
Market closed | Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems. Its focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Its filtration products are used in process development and process scale (clinical and commercial) production. Its XCell ATF systems are used in upstream perfusion (continuous) and N-1 (intensified fed-batch or hybrid perfusion) cell culture processing. Its chromatography franchise includes several products used in downstream purification, development, manufacturing and quality control of biological drugs. Its process analytics products complement and support its filtration, chromatography and protein franchises. Its TangenX product portfolio includes flat sheet (FS) tangential flow filtration (TFF) cassettes used primarily in downstream and ultrafiltration processes. Its desktop portfolio includes MAVERICK and MAVEN, REBEL, and ZipChip.

Key people

Tony John Hunt
Executive Chairman of the Board
Olivier Loeillot
President, Chief Executive Officer, Director
Jason K. Garland
Chief Financial Officer
James R. Bylund
Chief Operating Officer
Ralf Kuriyel
Senior Vice President - Research and Development
Karen A. Dawes
Lead Independent Director
Nicolas M. Barthelemy
Independent Director
Konstantin Konstantinov
Independent Director
Martin D. Madaus
Independent Director
Carrie Eglinton Manner
Independent Director
Click to see more

Key facts

  • EPIC
    RGEN
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US7599161095
  • Market cap
    $7.94bn
  • Employees
    1,778
  • Shares in issue
    56.18m
  • Exchange
    NASDAQ
  • Index
    S&P 400 Mid Cap, TR Equity United States Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.